Navigation Links
ASTRO publishes palliative radiotherapy for bone metastases guideline
Date:2/17/2011

The American Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality Committee has developed a guideline for the use of radiation therapy in treating bone metastases. The guideline will be published in the International Journal of Radiation OncologyBiologyPhysics, an official journal of ASTRO.

Bone metastases are caused when a malignant tumor spreads to the bone. They can lead to debilitating effects including pain, fractures and paralysis due to spinal cord compression. The care of these patients requires collaboration between several types of cancer treatment specialists.

External beam radiation therapy (EBRT) provides successful pain relief in 50 to 80 percent of patients with little risk of side effects. However, the widespread variation in practice patterns between radiation oncologists presented an opportunity to standardize care through the construction of a formal treatment guideline.

Some of the committee's findings include:

  1. EBRT continues to be the mainstay for treating bone metastases.

  2. Both single doses and longer courses of radiation have shown similar pain relief outcomes, and each has advantages. A single course has proven more convenient for patients and caregivers, while longer courses have a lower incidence of repeat treatment to the same site.

  3. Repeat irradiation with EBRT might be feasible in some circumstances, though the details of its effectiveness and safety are still to be determined.

  4. Bisphosphonates do not eliminate the need for EBRT for painful metastases, and they act effectively when combined with EBRT.

  5. Stereotactic body radiation therapy can be considered for patients with a newly discovered or recurrent tumor in the spinal column or paraspinal areas; however, it is suggested that stereotactic treatment be reserved for patients who meet specific criteria, who are treated at centers with sufficient training and experience, and who are part of a therapeutic trial.

  6. Radionuclides are most appropriate for patients who have several sites of painful osteoblastic metastases (like those that are commonly associated with prostate cancer) that cannot be conveniently or safely treated with EBRT.

  7. Surgical decompression and stabilization plus postoperative radiation therapy should be considered for some patients with single-level spinal cord compression or spinal instability.

    Stephen Lutz, M.D., lead author of the guideline and a radiation oncologist at Blanchard Valley Regional Cancer Center in Findlay, Ohio, said, "Radiation therapy is commonly used to treat bone metastases and has been proven very effective, but with the variety of radiation therapies available and range of successful fractionation schedules, it's important to provide physicians with this guideline to assure they are using the most appropriate methods in treating patients."


    '/>"/>


Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Senate Committee Advances Disastrous Idaho Health Freedom Act
2. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
3. ASTRO awards 17 Advocacy Day travel grants
4. ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
5. Santa Monica Jury Rejects Claims of Catastrophic Brain Injury From Exposure to Mold; Plaintiff Faces Motions for Attorney Fees and Costs
6. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
7. A new endoscopic technique for gastrointestinal perforations: the over-the-scope-clip
8. ASTRO president speaks on prostate cancer at MEDCAC meeting
9. ASTRO applauds nomination of Dr. Donald Berwick to head Centers for Medicare and Medicaid Services
10. Outstanding young gastroenterologists receive AGA Foundation
11. Outstanding young gastroenterologists receive AGA Foundation 2010 Research Scholars Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of the nationally ... Your Health on VoiceAmerica, recently talked on her program about how she is looking ... to remind listeners of an important distinction. World Water Day, Kleyne pointed out, is ...
(Date:3/23/2017)... Segundo, CA (PRWEB) , ... March 23, 2017 ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys ... source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted ...
(Date:3/23/2017)... Church, VA (PRWEB) , ... ... ... Clinical Evaluation Reports: Complying with European Guidelines and the New MEDDEV 2.7/1 ... – 3:00 p.m. ET, http://www.fdanews.com/mdclineval                  , How will the new ...
(Date:3/23/2017)... ... 2017 , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call ... is the creation of published author, Desiree M Webb, a registered nurse, minister of ... been happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys ...
(Date:3/23/2017)... ... ... a simple and strong explanation of the God’s love. “More Corruption” is the creation of ... God to write a book about Him. , She says, “I’m fed up with mortals ... the Lord God. They have not walked in my shoes and I know they never ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 /PRNewswire/ ... the NASDAQ Composite ended the trading session at ... edged 0.03% lower, to finish at 20,661.30; and ... 0.19%. Gains were broad based as six out ... This Thursday, Stock-Callers.com has initiated reports coverage on ...
(Date:3/23/2017)... Mass. , March 23, 2017 Merrimack ... enrollment of its first patient in a Phase 1 ... antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and ... is overexpressed in 50-100% of many major tumor types, ... "The initiation of this study is an ...
Breaking Medicine Technology: